Replies to post #253207 on Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

I agree about cherry picking or as pharma calls it 'highlighting' in PR. Things really get unfortunate when cherry picking manages to get into coverage of FDA approvals. Years back I once listened an eminent cancer physician start his put down of a kidney cancer drug candidate: "Now, when we have temsirolimus, do we really need another kidney cancer drug?" He had read PR plus what was in FDA label. Only.

I would add a guidance about night driving which applies nicely to biopharma PR:

Don't look at the light - it may blind you. Look beside it i.e. what was left unsaid. It is usually in plain sight.